GOLD 2023 COPD Report: Major Revisions from the Global Initiative for COPD
🔓 Free Teaser Guideline Pulmonology / Respiratory Practice-changing Grade: Moderate
Agustí A, Celli BR, Criner GJ, et al.
Apr 1, 2023 · Published in: Eur Respir J
The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.
2019 ATS/IDSA Community-Acquired Pneumonia Guideline: Practice-Defining Updates
🔓 Free Teaser Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Moderate
Metlay JP, Waterer GW, Long AC, et al.
Oct 1, 2019 · Published in: Am J Respir Crit Care Med
Also in Pulmonology / Respiratory
The 2019 ATS/IDSA CAP guideline introduces major shifts in diagnostic and empiric therapy strategies for adult patients.
Montelukast Linked to Higher ADHD and Conduct Risk Versus Inhaled Steroids
Analysis Pediatrics Confirmatory Grade: Low
Jiao XF, Ducharme FM, Leal LF, et al.
Oct 2, 2026 · Published in: BMC Medicine
Also in Psychiatry / Psychopharmacology, Pulmonology / Respiratory
Montelukast may increase neuropsychiatric risks in children with asthma.
Isavuconazole for chronic pulmonary aspergillosis: tolerability and TDM-guided dosing
Analysis Infectious Disease / Antimicrobials Hypothesis-generating Grade: Low
Fama F, Conflitti C, Civati A, et al.
Sep 16, 2026 · Published in: Antimicrobial Agents and Chemotherapy
Also in Pulmonology / Respiratory, Pharmacokinetics / TDM
Standard isavuconazole dosing often overshoots in chronic pulmonary aspergillosis, so early troughs can guide a step down to 100 mg daily.
Pharmacotherapy Reshapes Obstructive Sleep Apnea Management Toward Endotype-Driven Care
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Moderate
Zhou R, Yin G, Zhu Y, et al.
Aug 27, 2026 · Published in: Journal of Clinical Medicine
Also in Pulmonology / Respiratory
New drug options show promise for improving sleep apnea treatment beyond CPAP.
First-Trimester Inhaled Steroid Continuation Shows No Excess Pregnancy Risk
Analysis Women's Health / Reproductive Confirmatory Grade: Moderate
Suh B, Cho Y, Choi EY, et al.
Aug 24, 2026 · Published in: JAMA Network Open
Also in Pulmonology / Respiratory
Continue ICS during pregnancy to safely control asthma.
MARCH: Mucoactive Agents Fail and Harm in Ventilated Patients
★ Editor's Pick Analysis Critical Care / ICU Practice-changing Grade: Moderate
Connolly B, Dickson N, Campbell C, et al.
Aug 19, 2026 · Published in: NEJM
Also in Pulmonology / Respiratory
Carbocisteine and hypertonic saline did not shorten ventilation in nearly 2,000 ICU patients, and both added harm.
AAIITO Expert Consensus Reframes Mild-to-Moderate Asthma Toward Proactive Control
Consensus Statement Pulmonology / Respiratory Confirmatory Grade: Low
Martini M, Cecchi L, Musarra A, et al.
Aug 6, 2026 · Published in: Respiratory Medicine
Expert consensus offers new guidelines for mild-to-moderate asthma management.
Pharmacist Inhaler Review Cuts Readmissions in COPD, Not Overall
Analysis Pulmonology / Respiratory Hypothesis-generating Grade: Moderate
Parrott TD, Wallace MD, Eble SH, et al.
Aug 4, 2026 · Published in: CHEST Pulmonary
Pharmacist intervention cuts COPD readmissions effectively.
No Mortality Advantage for Higher-Dose Steroids in Pneumonia
Analysis Critical Care / ICU Confirmatory Grade: Low
Ouyang Y, Lai J, Wang P, et al.
Jul 5, 2026 · Published in: Critical Care
Also in Infectious Disease / Antimicrobials, Pulmonology / Respiratory
Lower and higher corticosteroid doses both reduce pneumonia mortality.
JCS/JPCPHS 2025 Guideline Reshapes Pulmonary Hypertension and VTE Management
★ Editor's Pick Guideline Cardiology Practice-changing Grade: Moderate
Tamura Y, Kusunose K, Yamashita Y, et al.
Jul 1, 2026 · Published in: Circulation Journal : Official Journal of the Japanese Circulation Society
Also in Anticoagulation / Hematology, Pulmonology / Respiratory
New 2025 guidelines set standards for PH and DVT management.
GOLD 2026 COPD Strategy: Mepolizumab Enters the Algorithm
Guideline Pulmonology / Respiratory Practice-changing Grade: Moderate
Dec 8, 2025 · Published in: Global Initiative for Chronic Obstructive Lung Disease (GOLD)
GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.
GINA 2021: Two-Track Asthma Strategy Replaces SABA-Only Reliever Reliance
Guideline Pulmonology / Respiratory Practice-changing Grade: Moderate
Reddel HK, Bacharier LB, Bateman ED, et al.
Jan 1, 2022 · Published in: Eur Respir J
GINA 2021 formalizes ICS-formoterol as the preferred reliever across all adult/adolescent steps and adds new pediatric and Step 5 options.
2016 ATS/IDSA HAP/VAP Guideline: HCAP Retired, Antibiograms Prioritized
Guideline Infectious Disease / Antimicrobials Practice-changing Grade: Low
Kalil AC, Metersky ML, Klompas M, et al.
Sep 1, 2016 · Published in: Clin Infect Dis
Also in Critical Care / ICU, Pulmonology / Respiratory
The 2016 ATS/IDSA update reshapes empiric antibiotic selection, de-escalation, and duration of therapy for hospital-acquired and ventilator-associated pneumonia around local resistance data and pharmacokinetic optimization.